First Randomized Trial of Generative AI Therapy Chatbot Shows Significant Mental Health Benefits

Dartmouth researchers have published the results of the first randomized controlled trial of a generative AI-powered therapy chatbot, with findings showing significant improvements across depression, anxiety, and eating disorder symptoms. The study, published in NEJM AI, tested Therabot with 210 adults over four weeks.

Participants with major depressive disorder experienced a striking 51% average reduction in symptoms, representing clinically meaningful improvements in mood and overall well-being. Those with generalized anxiety disorder saw a 31% average symptom reduction, with many moving from moderate to mild anxiety or below the diagnostic threshold entirely. Even among those at risk for eating disorders — traditionally more challenging to treat — users showed a 19% reduction in body image and weight concerns.

Study participants reported trust and communication levels comparable to working with a human mental health professional. The researchers noted that while AI therapy still requires clinician oversight, it has genuine potential to provide real-time support for the many people who lack regular access to mental health care.

The trial represents a landmark moment for digital therapeutics. With over half the global population living in areas with severe mental health professional shortages, AI-assisted therapy could help bridge a critical gap — though researchers emphasize that it should complement, not replace, human clinicians.